InMed Pharmaceuticals Inc.
INM
$2.12
-$0.23-9.66%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 7.71% | -23.10% | -74.20% | 33.86% | -472.61% |
| Total Depreciation and Amortization | -13.69% | -14.00% | -15.40% | -2.95% | 0.60% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -34.51% | 17.11% | -79.75% | -71.82% | 143.96% |
| Change in Net Operating Assets | -127.18% | 163.37% | 86.74% | -449.63% | 352.60% |
| Cash from Operations | -72.80% | 14.21% | -35.39% | 15.98% | -56.44% |
| Capital Expenditure | -- | -- | -- | -- | 100.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | 100.00% | -- | 100.00% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 4,396,900.00% | -- | -92.40% | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | 89.75% | -- | -- |
| Cash from Financing | 4,087,200.00% | -- | -92.73% | -- | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 721.57% | 165.16% | -177.37% | 54.53% | -48.81% |